文献速递医院感染防控艾滋病与性传播感染

GBS6疫苗在乌干达HIV感染与非感染孕妇中的安全性和免疫原性:一项双盲随机安慰剂对照2期试验

Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial.
PubMed 文献 · Lancet Infect Dis · 2026-08-25

在乌干达5家产前保健机构开展的2期双盲随机安慰剂对照试验,纳入300名孕妇(150名HIV感染,150名未感染),评估20 μg GBS6疫苗的安全性、反应原性和免疫原性。结果显示,HIV感染与未感染孕妇接种后抗体浓度无统计学显著差异,疫苗诱导的抗体可转移至婴儿,安全性良好,不良事件与疫苗无关。

要点

  • GBS6疫苗在HIV感染和未感染孕妇中均安全,严重不良事件与疫苗无关。
  • HIV感染与未感染孕妇接种后1个月抗体浓度无统计学显著差异。
  • 疫苗诱导的抗体可经胎盘转移至婴儿,HIV暴露与非暴露婴儿应答相似。

核心结论

  • GBS6疫苗在HIV感染和未感染孕妇中诱导的抗荚膜多糖抗体可转移至婴儿,安全性和免疫原性无HIV状态差异。

研究设计与样本

  • 双盲、随机、安慰剂对照的2期临床试验,在乌干达坎帕拉5家产前保健机构开展。
  • 纳入300名18-40岁、孕27周+0天至35周+6天、低风险单胎妊娠孕妇,按HIV状态分层区组随机(1:1)分配至20 μg GBS6疫苗组或安慰剂(生理盐水)组。

主要发现

  • 接种后7天内征集的不良事件多为轻至中度且短暂。
  • 共记录86例严重不良事件:GBS6组未感染HIV孕妇25例、感染HIV孕妇18例,安慰剂组未感染HIV孕妇25例、感染HIV孕妇18例;其中1例死亡(1%)为安慰剂组HIV感染孕妇疑似中毒。
  • 298例出生中5例(2%)死胎:GBS6组HIV感染孕妇1例(1%),安慰剂组未感染HIV孕妇1例(1%),安慰剂组HIV感染孕妇3例(4%)。
  • 婴儿中55例严重不良事件均与研究疫苗无关;2例死亡(4%):安慰剂组1例早期新生儿死亡(多发先天畸形和出生窒息),GBS6组1例4月龄婴儿猝死(窒息)。

关键数值与推荐

  • 疫苗剂量为20 μg GBS6(含血清型Ia-V),在标准破伤风和白喉疫苗接种后2周接种。
  • 主要结局为接种后2周、1个月、分娩时、产后6周、18周、6个月和12个月的母婴安全性。

临床怎么用

  • GBS6疫苗可在HIV感染孕妇中安全使用,不增加疫苗相关严重不良事件。
  • HIV感染状态不影响孕妇对GBS6的抗体应答,疫苗诱导的抗体可转移至婴儿。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunisation in pregnancy against group B streptococcus could reduce severe disease in early infancy; however, there are few data on the safety and immunogenicity of vaccines given to women living with HIV and their infants. We aimed to evaluate the safety, tolerability, and immunogenicity of the hexavalent capsular polysaccharide conjugate group B streptococcus vaccine (GBS6) in pregnant women living with and without HIV, assess infant outcomes, and quantify the placental transfer of vaccine-induced antibodies to their infants. METHODS: We conducted a double-blind, randomised, placebo-controlled, phase 2 clinical trial evaluating the safety, reactogenicity, and immunogenicity of 20 μg GBS6 compared with placebo in pregnant women living with HIV or without HIV in five antenatal care facilities in Kampala, Uganda. Women aged 18-40 years, between 27 weeks + 0 days and 35 weeks + 6 days, with a low-risk singleton pregnancy were randomly assigned (1:1) to receive placebo (normal saline) or GBS6 vaccine containing serotypes Ia-V, which were given 2 weeks after standard of care tetanus and diphtheria vaccination. We used stratified block randomisation by maternal HIV status, with a block size of eight. The unblinded site pharmacist prepared the investigational product in syringes that were fully masked with opaque labels before being provided to the vaccination nurse, thereby maintaining blinding of both study staff and participants. The primary outcomes were maternal and infant safety following vaccination assessed in all participants 2 weeks post-vaccination, 1 month post-vaccination, at delivery, 6 weeks after delivery, 18 weeks after delivery, 6 months after delivery, and 12 months after delivery. Secondary outcomes included maternal and infant antiserotype-specific group B streptococcus-capsular polysaccharide IgG concentrations and placental transfer of vaccine-induced antibodies at delivery and 18 weeks after delivery, summarised as geometric mean concentrations with 95% CIs, and were assessed in the modified intent-to-treat population. The study was registered at ClinicalTrials.gov (NCT05832502). FINDINGS: Between Oct 25, 2022, and Oct 22, 2024, 300 pregnant women (150 [50%] living with HIV and 150 [50%] without HIV) were randomly assigned to receive either GBS6 or placebo. The mother and infant pair were followed up until 12 months after delivery. Solicited adverse events reported up to 7 days post-vaccination were mostly mild-to-moderate and transient. In total, 86 serious adverse events were recorded: 25 among GBS6-vaccinated women without HIV, 18 among GBS6-vaccinated women living with HIV, 25 among women without HIV receiving placebo, and 18 among women living with HIV receiving placebo. Of 86 serious adverse events, one death (1%) occurred due to suspected poisoning: a woman living with HIV who received a placebo. Of 298 births, there were five (2%) stillbirths: one (1%) among 74 women living with HIV who received the GBS6 vaccine, one (1%) among 74 women without HIV who received placebo, and three (4%) among 76 women living with HIV who received placebo. All serious adverse events, including maternal death, were not related to the study vaccine. There were 55 serious adverse events among the infant participants, all of which were deemed unrelated to the study vaccine. Two (4%) deaths occurred: one early neonatal death (multiple congenital anomalies and birth asphyxia) in the placebo group and one sudden infant death (asphyxia) at age 4 months in the GBS6 group. GBS6 induced maternal antibody concentration to all serotypes, with no statistically significant differences observed between pregnant women living with and without HIV 1 month following vaccination. The geometric mean concentrations for pregnant women living with HIV compared with pregnant women without HIV were Ia 12·02 (6·42-22·50) versus 9·38 (5·06-17·41; p=0·575), Ib 3·71 (2·12-6·48) versus 2·52 (1·35-4·71; p=0·362), II 19·50 (12·93-29·41) versus 17·92 (11·76-27·31; p=0·776), III 4·38 (2·54-7·55) versus 5·64 (3·66-8·70; p=0·469), IV 4·26 (2·78-6·53) versus 4·53 (2·88-7·13; p=0·842), and V 0·49 (0·34-0·70) versus 0·52 (0·31-0·85; p=0·870). There was no evidence of a difference in maternal antibody responses between pregnant women living with HIV and without HIV. GBS6 induced strong early antibody concentrations that declined over time but remained higher than placebo at 1 year after delivery, and HIV-exposed infant showed similar responses to the HIV-unexposed infants. INTERPRETATION: GBS6 elicited anti-capsular polysaccharide conjugate antibodies against group B streptococcus in pregnant women that were transferred to their infants, with no evidence of a difference irrespective of HIV status. No statistically significant difference was seen in pregnant women living with HIV compared with pregnant women not living with HIV or their infants in either safety or immunogenicity, suggesting that this vaccine could be used safely in pregnant women living with HIV. FUNDING: The European & Developing Countries Clinical Trials Partnership.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mboizi R, Sekikubo M, Businge GB, et al. Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial. Lancet Infect Dis. 2026. PMID: 42641635. doi:10.1016/S1473-3099(26)00318-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。